LBA81_PRPhase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-na ïve NSCLC: Initial results from the ALK+ cohort

ConclusionsBlood-based detection of ALK fusions results in high ORR and clinical benefit in pts receiving alectinib. These data validate the clinical utility of blood-based NGS as an additional method to inform clinical decision-making in ALK+ NSCLC.Clinical trial identificationNCT03178552.Editorial acknowledgementMedical Writing support was provided by Nicola Griffin of Gardiner-Caldwell Communications and funded by F. Hoffmann-La Roche.Legal entity responsible for the studyF. Hoffmann-La Roche Ltd.FundingF. Hoffman-La Roche Ltd.DisclosureS.M. Gadgeel: Honoraria (self), Advisory / Consultancy: Ariad, AstraZeneca, Bristol-Myers Squibb, Pfizer and F. Hoffmann-La Roche Ltd/Genentech. T.S.K. Mok: Leadership role: Sanonics Ltd; Honoraria (self), Advisory / Consultancy: ACEA Biosciences, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chimed, Cirina, Fishawack Facilitate, Ignyta, Janssen, Lilly, Merck Serono, Merck Sharp&Dohme, Novartis, OncoGenex, Pfizer, F. Hoffmann-La Roche Ltd/Genentech, SFJ Pharm; Research grant / Funding (self): AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, Merck Sharp&Dohme, Novartis, Pfizer, F. Hoffmann-La Roche Ltd, SFJ Pharmaceutical and XCovery. S. Peters: Honoraria (self), Advisory / Consultancy: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Eli Lilly, F. Hoffmann-La Roche Ltd, Janssen, Merck Sharp&Dohme, Merck Serono, Novartis, Pfizer, Regeneron and Takeda; Speaker Bureau / Expert t...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionThis pilot study showed that MSAF could be another good indicator of therapeutic response, and clonal analysis could be clinically useful in monitoring clonal dynamics and detecting remote metastasis and early relapse.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
CONCLUSION: A history of asthma may be associated with a higher grade of pneumonitis if it develops, and a history of smoking may augment this relationship. PMID: 31665718 [PubMed - as supplied by publisher]
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
Results from a phase III clinical trial comparing Keytruda (pembrolizumab) to standard chemotherapy shows the immunotherapy drug still has a long way to go as a viable treatment option for malignant pleural mesothelioma. Keytruda did not improve progression-free survival for mesothelioma patients who progressed after first-line chemotherapy. The disappointing results from the PROMISE-meso study were presented at the European Society of Medical Oncology (ESMO) annual meeting last week. It was the first randomized trial comparing progression-free survival between immunotherapy and first-line chemotherapy for mesothelioma p...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusion: This first-in-human study demonstrates that 99mTc-labeled anti–PD-L1-single-domain antibody SPECT/CT imaging is safe and associated with acceptable dosimetry. Tumor uptake is readily visible against background tissues, particularly at 2 h when the T:BP ratio correlates with PD-L1 immunohistochemistry results.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Source Type: research
We report on a case of pseudoprogression, which was presented as intestinal perforation after pembrolizumab immunotherapy for NSCLC. A-54-year-old man with stage IV NSCLC received pembrolizumab therapy. The patient was admitted to our hospital because of acute abdominal pain and the computed tomography scan revealed diffuse wall thickening of the small bowel with free intraperitoneal air. Intestinal perforation was suspected and surgical resection was performed. Histological evaluation of the resected specimen showed infiltrated lymphocytes positive for CD3, CD8 with necrotic tumor cells, suggestive of an immune reaction. ...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
This study quantifies the disturbing trend that, despite the expansion in the number of patients eligible for expensive and potentially toxic ICIs [immune checkpoint inhibitors], the ratio of those benefiting is decreasing,” wrote Dr. Daniel V.T. Catenacci, co-author of an editorial that accompanied the study in JAMA Network. “Observations in this article are sobering and remind us to keep expectations realistic.” Both Catenacci and Haslem agreed that the study should serve as a reminder to patients, physicians and policy makers to have more realistic discussions about the use of, and expectations of, the...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
In a study led by UCLA investigators, treatment with the immunotherapy drug pembrolizumab helped more than 15% of people with advanced non-small cell lung cancer live for at least five years — and 25% of patients whose tumor cells had a specific protein lived at least that long.When the study began in 2012, the average five-year survival rate was just 5.5%  for people with that type of cancer.The study, conducted by researchers at theUCLA Jonsson Comprehensive Cancer Center and more than 30 other centers, was the first to evaluate pembrolizumab as a treatment for lung cancer. The results were featured in aJune 1...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
ConclusionsThe findings indicate that the PERCIST-based evaluation could identify progressive disease earlier. Early identification of nonresponders could lead to prevention of overtreatment and to an early switch to a  more effective therapy.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: This first in human study demonstrates that 99mTc-labeled anti-PD-L1-sdAb SPECT/CT imaging is safe and associated with acceptable dosimetry. Tumor uptake is readily visible against background tissues, particularly at 2h when the T:BP ratio correlates with IHC PD-L1 expression.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Lung Cancer I: Molecular Biomarkers and Molecular Imaging Signatures Source Type: research
Conclusions: Hypermetabolic changes on DTP 18F-FDG PET showed good correlation with tumor positive expression of PD-L1 and high density of CD8 TILs and PD-1 in tumor immune microenvironment. Furthermore, dSUVmax was an independent predictor of PD-L1 expression in pretreated NSCLC.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Lung Cancer I: Molecular Biomarkers and Molecular Imaging Signatures Source Type: research
More News: AstraZeneca | Brain | Cancer & Oncology | Clinical Trials | Employment | Genetics | Grants | Immunotherapy | Legislation | Merck | Neurology | Non-Small Cell Lung Cancer | PET Scan | Pfizer | Study